Vodafone (NYSE: VOD) Ventures has invested an undisclosed sum in t+Medical, a British provider of mobile technology used to transfer patient biometric data. The funding from the corporate VC arm of the global telecoms group will be used to help the mobile medical platform firm roll outs its mPRO platform, which facilitates the collection of patient data in clinical trials using a mobile device. Subjects taking part in a trial enter data into an interactive diary programme on their mobiles. The information can then be securely downloaded on t+servers where it can be analyzed (release).